Skip to main content
Akeso, Inc. logo

Akeso, Inc. — Investor Relations & Filings

Ticker · 9926 ISIN · KYG0146B1032 LEI · 254900ECWYGR3QW5GF30 HKEX Manufacturing
Open in API
Filings indexed 334 across all filing types
Latest filing 2025-10-08 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 9926

About Akeso, Inc.

http://www.akesobio.com

Akeso, Inc. is a commercial-stage biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs globally. The company integrates comprehensive drug discovery capabilities, including target validation and antibody drug development. Akeso maintains a broad and innovative therapeutic portfolio, primarily concentrated in the fields of oncology and immunology. The company has successfully advanced multiple novel therapies, including five innovative drugs with approved indications, demonstrating its commitment to bringing breakthrough treatments to market. Akeso has notably developed a lung cancer drug that has garnered significant attention within the global biotech sector.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2025
Share Issue/Capital Change Classification · 1% confidence The document is the FF301 Monthly Return filed with HKEX under Listing Rule Chapter 19B, detailing movements in authorised and issued share capital, treasury shares, share option schemes, and a primary placing (placement of 23,550,000 new shares). It is the actual return (not merely a link to a report) and centers entirely on share issuance and capital changes. According to the taxonomy, this falls under “Share Issue/Capital Change” (SHA).
2025-10-08 English
2025 INTERIM REPORT
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled '2025 INTERIM REPORT' and contains comprehensive financial statements, including the 'Interim Condensed Consolidated Statement of Profit or Loss', 'Interim Condensed Consolidated Statement of Financial Position', and 'Management Discussion and Analysis'. It covers a period shorter than a full fiscal year (six months ended June 30, 2025). It meets all criteria for an Interim/Quarterly Report. H1 2025
2025-09-30 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 1% confidence The document is a Next Day Disclosure Return (FF305) filed pursuant to Hong Kong Main Board and GEM listing rules, detailing changes in the company’s issued share capital (placement of new shares, opening and closing balances, issue price per share). It is clearly an announcement of a new share issue under a general mandate. This matches the definition of Share Issue/Capital Change (SHA).
2025-09-04 English
COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE AND PLACING OF EXISTING SHARES
Share Issue/Capital Change Classification · 1% confidence The announcement details the completion of a placing of new shares under the company’s general mandate and placing of existing shares, including the number of shares, placing price, net proceeds raised, and intended use of proceeds. This is an announcement of a share issue and related capital change rather than an earnings release, management discussion, or regulatory filing. Therefore, it should be classified under Share Issue/Capital Change (SHA).
2025-09-04 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2025
Regulatory Filings Classification · 1% confidence The document is a statutory "Monthly Return for Equity Issuer and Hong Kong Depositary Receipts" (Form FF301) filed with HKEX showing share capital movements, share options, placings, and related confirmations for the month of August 2025. It is a recurring exchange listing-rule compliance return rather than an annual report, earnings release, management discussion, or one-off capital transaction announcement. It does not present financial results, proxy materials, or AGM voting results. It is best classified as a general regulatory filing. Therefore, the appropriate category is Regulatory Filings (RNS).
2025-09-03 English
PLACING OF NEW SHARES UNDER GENERAL MANDATE AND PLACING OF EXISTING SHARES
Share Issue/Capital Change Classification · 1% confidence The document is a Hong Kong Stock Exchange announcement detailing the placement of new and existing shares under a general mandate, including share quantities, pricing, conditions, use of proceeds and fundraising history. It is not a full financial report or earnings release but rather a corporate action notice of equity issuance and capital change. This corresponds to a Share Issue/Capital Change announcement.
2025-08-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.